Statin drug interactions and related adverse reactions

Expert Opinion on Drug Safety

Volumn 11, Issue 6, 2012, Pages 933-946

  Bellosta, Stefano ^a   Corsini, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adverse drug reactions; Drugdrug interactions; HMG CoA reductase inhibitors; Polypharmacy; Statins

Indexed keywords

AMPRENAVIR; ATORVASTATIN; AZITHROMYCIN; CLARITHROMYCIN; CYCLOSPORIN; DARUNAVIR; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; FOSAMPRENAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR; MEVINOLIN; MIBEFRADIL; NEFAZODONE; NELFINAVIR; PITAVASTATIN; POSACONAZOLE; PRAVASTATIN; RAPAMYCIN; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; TELITHROMYCIN; UNINDEXED DRUG; VERAPAMIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOGENETICS; POLYPHARMACY; PRIMARY PREVENTION; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREND STUDY;

CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICATION ADHERENCE; PHARMACOGENETICS;

EID: 84867773207     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.712959     Document Type: Review

References (106)

1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
2. Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. Brunton BCL, Knollman B, editors. Mc Graw Hill, New York: 2011. p. 877-908
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32
5. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217(Suppl 1):S1-44
6. Tomaszewski M, Stepien KM, Tomaszewska J, et al. Statin-induced myopathies. Pharmacol Rep 2011;63:859-66
7. Bader T. Yes! Statins can be given to liver patients. J Hepatol 2012;56:305-7
8. FDA. Statin Drugs-Drug Safety Communication: Class Labeling Change. 2012.Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm293670.htm [Last accessed 27 June 2012]
9. Corsini A. Statin-related muscle complaints: an underestimated risk. Cardiovasc Drugs Ther 2005;19:379-81
10. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14
11. FDA Drug Safety Communication: FDA Expands Advice on Statin Risks. 2011.Available from: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330. htm?utm-source=fdaSearch& utm-medium=website& utm-term=statin&utm- content=1 [Last accessed 1 April 2012]
12. FDA. Drug Safety Communication: Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. 2012.Available from: http://www.fda.gov/Drugs/DrugSafety/ ucm293877.htm? utm-source=fdaSearch& utm-medium=website&utm-term=statin %20muscle&utm-content=1 [Last accessed 1 April 2012]
13. FDA. Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. 2012.Available from: http://www.fda.gov/ Drugs/DrugSafety/ucm293101.htm? utm-source=fdaSearch&utm-medium= website&utm-term=safety%20changes% 20to%20cholesterol-lowering%20statin% 20drugs&utm-content=1 [Last accessed 26 March 2012]
14. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:52C-60C
15. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97:69C-76C
16. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001;175:486-9
17. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376:1658-69
18. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:III50-7
19. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005;17:123-32
20. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J
21. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95
22. Heerey A, Barry M, Ryan M, et al. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000;169:176-9
23. Bakhai A, Rigney U, Hollis S, et al. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf 2012;21:485-93
24. Rowland M, Tozer TN. Clinical pharmacokinetics. Concepts and applications. Media: 3rd, 1995
25. Egger SS, Ratz Bravo AE, Hess L, et al. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 2007;24:429-40
26. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-28
27. Corsini A, Bellosta S. Drug-drug interaction with statins. Expert Rev Clin Pharmacol 2008;1:105-13
28. Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin 2011;27:1551-62
29. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105
30. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010;10:11-28
31. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009;5:703-29
32. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 2003;33:27-41
33. Cilla DD Jr, Whitfield LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996;60:687-95
34. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006;97:27C-31C
35. Giorgi MA, Caroli C, Arazi HC, et al. Pharmacogenomics and adverse drug reactions: the case of statins. Expert Opin Pharmacother 2011;12:1499-509
36. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90
37. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64:369-77
38. Mousa O, Brater DC, Sunblad KJ, et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000;67:267-74
39. Lewin JJ III, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother 2002;36:1546-9
40. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001;89:117-18
41. Park CG, Lee H, Choi JW, et al. Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Int J Clin Pharmacol Ther 2010;48:497-503
42. Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010;33:171-87
43. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-2
44. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280-7
45. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505-12
46. Kyrklund C, Backman JT, Neuvonen M, et al. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003;73:538-44
47. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 2003;17:265-85
48. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein- mediated secretion. J Clin Pharmacol 2000;40:91-8
49. Gallelli L, Ferraro M, Spagnuolo V, et al. Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. Drug Metabol Drug Interact 2009;24:83-7
50. Mackay J, Fenech M, Myint K. Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin. Br J Hosp Med (Lond) 2012;73:106-7
51. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011;57:1251-63
52. Borders-Hemphill V. Concurrent use of statins and amiodarone. Consult Pharm 2009;24:372-9
53. Marot A, Morelle J, Chouinard VA, et al. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg 2011;66:134-6
54. Merz T, Fuller SH. Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone. Am J Health Syst Pharm 2007;64:1818-21
55. Nagele H, Behrens S, Hashagen S, et al. Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy. Drug Metabol Drug Interact 2007;22:195-200
56. FDA. Drug Safety Communication: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone. 2011.Available from: http://www.fda.gov/Drugs/DrugSafety/ucm283137.htm [Last accessed 6 April 2012]
57. Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf 2012;11:439-44
58. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81
59. Ryu HJ, Song R, Kim HW, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol 2012. [Epub ahead of print]
60. Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007;110:4588-98
61. Penel N, Blay JY, Adenis A. Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 2008;358:2746-7
62. Filppula A, Laitila J, Neuvonen P, et al. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 2012;165:2787-98
63. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003;89:1855-9
64. Hardwicke RL, Lewis ST, Grimes RM. Evaluation and pharmacologic management of the HIV-infected patient with dyslipidemia. J Assoc Nurses AIDS Care 2010;21:429-38
65. Aberg JA. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009;50:54-64
66. Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am 2009;38:207-22
67. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-27
68. Lo J. Dyslipidemia and lipid management in HIV-infected patients. Curr Opin Endocrinol Diabetes Obes 2011;18:144-7
69. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008;9:72-81
70. Malvestutto CD, Aberg JA. Management of dyslipidemia in HIV-infected patients. Clin Lipidol 2011;6:447-62
71. Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med 2010;268:530-9
72. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60
73. Drewe J, Gutmann H, Fricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999;57:1147-52
74. Perloff MD, Von Moltke LL, Marchand JE, et al. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 2001;90:1829-37
75. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195-211
76. Moreno A, Fortun J, Graus J, et al. Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia. Liver Transpl 2011;17:331-3
77. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31
78. Aliabadi AZ, Mahr S, Dunkler D, et al. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 2008;86:1771-6
79. Amundsen R, Christensen H, Zabihyan B, et al. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos 2010;38:1499-504
80. Dopazo C, Bilbao I, Lazaro JL, et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transplant Proc 2009;41:1021-4
81. Lin JC, Ito MK. A drug interaction between troglitazone and simvastatin. Diabetes Care 1999;22:2104-6
82. Kyrklund C, Backman JT, Kivisto KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000;68:592-7
83. Murphy MJ, Dominiczak MH. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 1999;75:359-60
84. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:518-24
85. Bailey KM, Romaine SP, Jackson BM, et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet 2010;3:276-85
86. Akao H, Polisecki E, Kajinami K, et al. Genetic variation at the SLCO1B1 gene locus and low-density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis 2012;220:413-17
87. Ieiri I, Suwannakul S, Maeda K, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2007;82:541-7
88. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genome-wide study. N Engl J Med 2008;359:789-99
89. Furihata T, Satoh N, Ohishi T, et al. Functional analysis of a mutation in the SLCO1B1 gene (c.1628T > G) identified in a Japanese patient with pravastatin-induced myopathy. Pharmacogenomics J 2009;9:185-93
90. Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis 2007;6:7
91. Quinzii C, Naini A, Salviati L, et al. A mutation in para- hydroxybenzoatepolyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006;78:345-9
92. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009;85:198-203
93. Agrawal AR, Tandon M, Sharma PL. Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects. Int J Clin Pract 2007;61:1812-18
94. Prasad GV, Wong T, Meliton G, et al. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002;74:1200-1
95. Dahan A, Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent and relevance. Eur J Clin Nutr 2004;58:1-9
96. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402
97. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83
98. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999;66:118-27
99. Lilja JJ, Kivisto KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 2000;68:384-90
100. Rogers JD, Zhao J, Liu L, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999;66:358-66
101. Shirasaka Y, Suzuki K, Nakanishi T, et al. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J Pharm Sci 2011;100:3843-53
102. Ming EE, Davidson MH, Gandhi SK, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol 2008;2:453-63
103. Stang P, Morris L, Kempf J, et al. The coprescription of contraindicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther 2007;14:30-40
104. Rowan CG, Brunelli SM, Munson J, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2012;21:494-506
105. Varma MV, Rotter CJ, Chupka J, et al. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm 2011;8:1303-13
106. Greupink R, Dillen L, Monshouwer M, et al. Interaction of fluvastatin with the liver-specific Na+-dependent taurocholate cotransporting polypeptide (NTCP). Eur J Pharm Sci 2011;44:487-96